U.S. Markets closed

Altimmune, Inc. (ALT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
15.76-0.65 (-3.96%)
At close: 4:00PM EST

16.01 +0.25 (1.59%)
After hours: 7:31PM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close16.41
Bid15.65 x 1200
Ask15.78 x 1000
Day's Range15.73 - 16.80
52 Week Range2.50 - 35.10
Avg. Volume1,770,396
Market Cap585.49M
Beta (5Y Monthly)1.36
PE Ratio (TTM)N/A
EPS (TTM)-1.91
Earnings DateMay 11, 2021 - May 17, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJan 20, 2017
1y Target Est41.83
  • Altimmune, Inc. (NASDAQ:ALT): Is Breakeven Near?
    Simply Wall St.

    Altimmune, Inc. (NASDAQ:ALT): Is Breakeven Near?

    Altimmune, Inc. ( NASDAQ:ALT ) is possibly approaching a major achievement in its business, so we would like to shine...

  • MarketWatch

    Positive news on COVID vaccines weighs against concerns over new variants

    The COVID-19 vaccine developed by Pfizer Inc. and German partner BioNTech SE has proved to be as effective in the real world as it was in clinical trials in the first major study of the two-dose regiment involving 1.2 million people in Israel.

  • MarketWatch

    Altimmune starts enrolling early-stage trial for its nasal spray COVID-19 vaccine candidate

    Shares of Altimmune Inc. were down 4.8% in trading on Thursday after the company said it started enrolling participants in a Phase 1 clinical trial for its COVID-19 vaccine candidate. Altimmune is developing a single-dose nasal spray vaccine. The study is expected to enroll up to 180 healthy adults between the ages of 18 and 55 years old, who will receive one of three doses of the experimental vaccine. The company said it expects to share the first batch of clinical data from this trial in the second quarter of this year. Altimmune's stock has soared 969.9% over the past 12 months, while the broader S&P 500 is up 21.7%.